📊 MGX Key Takeaways
Is MGX a Good Investment? Thesis Analysis
Metagenomi is a pre-revenue biotech company with severe cash burn and deteriorating fundamentals. Revenue declined 51.8% YoY to $25.2M while operating losses widened to -$96.0M, indicating the company is consuming cash at an unsustainable rate. At current burn rate of ~$89.5M annually in negative free cash flow against only $41.7M in cash reserves, the company faces imminent funding challenges within 6-12 months.
Why Buy MGX? Key Strengths
- Strong balance sheet with $158.6M stockholders equity
- Zero debt (Debt/Equity of 0.0x) provides financial flexibility
- Excellent liquidity position with 7.22x current ratio
MGX Investment Risks to Consider
- Massive operating losses of -$96.0M with -380.9% operating margin indicates core business is deeply unprofitable
- Negative operating cash flow of -$88.9M with free cash flow of -$89.5M; cash runway appears to be 5-6 months at current burn rate
- Revenue collapsed 51.8% YoY to $25.2M, signaling failed commercialization or clinical setbacks
- Diluted EPS of -$2.36 reflects severe shareholder dilution from funding rounds
- Negative ROE of -55.4% and ROA of -39.7% show value destruction
Key Metrics to Watch
- Monthly cash burn rate and runway until additional funding required
- Path to gross profitability and timeline for positive operating cash flow
- Revenue trajectory and clinical trial progression announcements
- Capital raise activities and dilution impact
MGX Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 7.22x current ratio provides a solid financial cushion.
MGX Profitability Ratios
MGX vs Healthcare Sector
How Metagenomi Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is MGX Overvalued or Undervalued?
Based on fundamental analysis, Metagenomi Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
MGX Balance Sheet & Liquidity
MGX 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Metagenomi Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-2.36 indicates the company is currently unprofitable.
MGX Growth Metrics (YoY)
MGX Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $8.7M | -$10.7M | $-0.51 |
| Q2 2025 | $8.5M | -$10.7M | $-0.29 |
| Q1 2025 | $4.1M | -$25.0M | $-0.68 |
| Q3 2024 | $11.5M | -$10.7M | $-0.51 |
| Q2 2024 | $11.3M | -$10.7M | $-0.29 |
| Q1 2024 | $8.7M | -$16.1M | $-1.19 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
MGX Capital Allocation
MGX SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Metagenomi Therapeutics, Inc. (CIK: 0001785279)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MGX
What is the AI rating for MGX?
Metagenomi Therapeutics, Inc. (MGX) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MGX's key strengths?
Claude: Strong balance sheet with $158.6M stockholders equity. Zero debt (Debt/Equity of 0.0x) provides financial flexibility.
What are the risks of investing in MGX?
Claude: Massive operating losses of -$96.0M with -380.9% operating margin indicates core business is deeply unprofitable. Negative operating cash flow of -$88.9M with free cash flow of -$89.5M; cash runway appears to be 5-6 months at current burn rate.
What is MGX's revenue and growth?
Metagenomi Therapeutics, Inc. reported revenue of $25.2M.
Does MGX pay dividends?
Metagenomi Therapeutics, Inc. does not currently pay dividends.
Where can I find MGX SEC filings?
Official SEC filings for Metagenomi Therapeutics, Inc. (CIK: 0001785279) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MGX's EPS?
Metagenomi Therapeutics, Inc. has a diluted EPS of $-2.36.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MGX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Metagenomi Therapeutics, Inc. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MGX stock overvalued or undervalued?
Valuation metrics for MGX: ROE of -55.4% (sector avg: 15%), net margin of -348.5% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MGX stock in 2026?
Our dual AI analysis gives Metagenomi Therapeutics, Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MGX's free cash flow?
Metagenomi Therapeutics, Inc.'s operating cash flow is $-88.9M, with capital expenditures of $574.0K. FCF margin is -354.9%.
How does MGX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -348.5% (avg: 12%), ROE -55.4% (avg: 15%), current ratio 7.22 (avg: 2).